Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.68 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.68 |
| ▸ | TSHR | P16473 | 4/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.52 |
| ▸ | MAPT | P10636 | 4/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.52 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.52 |
| ▸ | PLIN1 | O60240 | 1/20 | 0.52 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.52 |
| ▸ | GMNN | O75496 | 1/20 | 0.52 |
| ▸ | KCNK2 | O95069 | 1/20 | 0.52 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.52 |
| ▸ | GSR | P00390 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11398188 | 0.90 | TDP1 (0.56) | TDP1L3MBTL1TSHRSMN1; SMN2ALDH1A1 | |
| SCHEMBL29627171 | 0.88 | TDP1 (0.70) | TDP1L3MBTL1TSHRSMN1; SMN2ALDH1A1 | |
| SCHEMBL329162 | 0.88 | TDP1 (0.70) | TDP1L3MBTL1TSHRSMN1; SMN2ALDH1A1 | |
| SCHEMBL16838391 | 0.87 | TDP1 (0.68) | TDP1L3MBTL1TSHRSMN1; SMN2ALDH1A1 | |
| SCHEMBL5764011 | 0.84 | TDP1 (0.64) | TDP1L3MBTL1TSHRSMN1; SMN2ALDH1A1 | |
| SCHEMBL50994 | 0.83 | TSHR (0.54) | TDP1L3MBTL1TSHRSMN1; SMN2ALDH1A1 | |
| SCHEMBL15971290 | 0.83 | CA12 (0.67) | TDP1L3MBTL1TSHRSMN1; SMN2ALDH1A1 | |
| SCHEMBL17335057 | 0.83 | TDP1 (0.62) | TDP1L3MBTL1TSHRSMN1; SMN2ALDH1A1 | |
| SCHEMBL4099183 | 0.82 | TDP1 (0.49) | TDP1L3MBTL1TSHRSMN1; SMN2ALDH1A1 | |
| SCHEMBL13983247 | 0.82 | MAPT (0.49) | TDP1L3MBTL1TSHRSMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 229 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113072441-A | Preparation method of 2-methoxy-6-methylbenzoic acid | 江苏永安化工有限公司 | 2021-07-06 | — | — | CN | claimed |
| EP-4688748-A1 | QUINOLINONE AMIDE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS, INC. (US) | 2026-02-11 | — | — | EP | disclosed |
| US-20260035354-A1 | PIPERIDINEDIONE DERIVATIVES | INNOCURE THERAPEUTICS, INC. (KR) | 2026-02-05 | — | — | US | disclosed |
| US-20260008791-A1 | CHEMICAL COMPOUNDS | BORAH INC (US) | 2026-01-08 | — | — | US | disclosed |
| US-20260008774-A1 | QUINOLINONE AMIDE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS INC (US) | 2026-01-08 | — | — | US | disclosed |
| EP-4640686-A1 | DEGRADER FOR DEGRADING BRD PROTEIN AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | Innocure Therapeutics, Inc. (KR) | 2025-10-29 | — | — | EP | disclosed |
| US-12448369-B2 | Quinolinone amide compounds and uses thereof | EDGEWISE THERAPEUTICS, INC. (US) | 2025-10-21 | — | — | US | disclosed |
| EP-4624472-A1 | DEGRADER INCLUDING NOVEL C-MET PROTEIN LIGAND AND PHARMACEUTICAL COMPOSITION INCLUDING SAME | Innocure Therapeutics, Inc. (KR) | 2025-10-01 | — | — | EP | disclosed |
| EP-4624466-A1 | DEGRADER FOR DECOMPOSING CMET PROTEIN, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Innocure Therapeutics, Inc. (KR) | 2025-10-01 | — | — | EP | disclosed |
| US-12384756-B2 | Piperidinedione derivatives | INNOCURE THERAPEUTICS, INC. (KR) | 2025-08-12 | — | — | US | disclosed |
| US-20030139451-A1 | Synthesis and anti-tumor activity of nitrogen substituted thalidomide analogs | CHILDREN'S MEDICAL CENTER CORPORATION, THE | 2003-07-24 | — | — | US | disclosed |
| US-20030064992-A1 | N-aryl (thio) anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors | ALTMANN KARL-HEINZ (CH) | 2003-04-03 | — | — | US | disclosed |
| WO-2003014315-A2 | SYNTHESIS AND ANTI-TUMOR ACTIVITY OF NITROGEN SUBSTITUTED THALIDOMIDE ANALOGS | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2003-02-20 | — | — | WO | disclosed |
| US-6448277-B2 | ANTITUOR AGENTS, ANTICARCINOGENIC AGENTS | NOVARTIS AG (CH) | 2002-09-10 | — | — | US | disclosed |
| US-20020019414-A1 | N-aryl(thio)anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2002-02-14 | — | — | US | disclosed |
| CN-1331680-A | N-aryl (thio) anthranilic acid amide derivatives, their prepn. and their use as VEGF receptor tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2002-01-16 | — | — | CN | disclosed |
| EP-1129075-A1 | N-ARYL(THIO)ANTHRANILIC ACID AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS VEGF RECEPTOR TYROSINE KINASE INHIBITORS | Novartis AG (CH) | 2001-09-05 | — | — | EP | disclosed |
| WO-2000027820-A1 | N-ARYL(THIO)ANTHRANILIC ACID AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS VEGF RECEPTOR TYROSINE KINASE INHIBITORS | NOVARTIS AG (CH) | 2000-05-18 | — | — | WO | disclosed |
| EP-0002624-B1 | 2-BENZAZEPINE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SMITHKLINE BECKMAN CORPORATION (US) | 1981-10-14 | — | — | EP | disclosed |
| EP-0002624-A1 | 2-Benzazepine compounds, processes for their preparation and pharmaceutical compositions containing them | SMITHKLINE BECKMAN CORPORATION (US) | 1979-06-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260008791-A1 | CHEMICAL COMPOUNDS | JAK3, JAK2, JAK1 | TDP1 615/4885L3MBTL1 3260/4885TSHR 635/4885 |
| US-20260035354-A1 | PIPERIDINEDIONE DERIVATIVES | CRBN, PSMC1, PSME3 | TDP1 4369/4885L3MBTL1 2779/4885TSHR 2240/4885 |
| US-20030139451-A1 | Synthesis and anti-tumor activity of nitrogen substituted thalidomide analogs | VEGFA, FLT4, FLT1 | TDP1 2625/4885L3MBTL1 2607/4885TSHR 3561/4885 |
| US-12448369-B2 | Quinolinone amide compounds and uses thereof | TNNI3, TNNT2, COQ8A | TDP1 1600/4885L3MBTL1 4118/4885TSHR 3265/4885 |
| US-20030064992-A1 | N-aryl (thio) anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors | AXL, TYRO3, NR2E3 | TDP1 2696/4885L3MBTL1 4343/4885TSHR 34/4885 |
| US-20020019414-A1 | N-aryl(thio)anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors | AXL, TYRO3, KDR | TDP1 2775/4885L3MBTL1 4472/4885TSHR 31/4885 |
| US-12384756-B2 | Piperidinedione derivatives | CRBN, CUL1, PSMB10 | TDP1 4149/4885L3MBTL1 2143/4885TSHR 3860/4885 |
| US-20260008774-A1 | QUINOLINONE AMIDE COMPOUNDS AND USES THEREOF | TNNT2, TNNI3, TNNC1 | TDP1 2708/4885L3MBTL1 3604/4885TSHR 339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.